Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

7h ago, source: Yahoo Finance

Arvinas, Inc. (ARVN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives ...

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

1d ago, source:

(Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created ...

Arvinas, Inc. (ARVN)

7d ago, source: Yahoo Finance

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news. Biotech stocks ...

Arvinas appoints new chief business officer

1d ago, source: Investing

NEW HAVEN, Conn. - Arvinas, Inc. (NASDAQ:ARVN), a biotechnology firm focused on developing therapies for serious diseases, announced today the promotion of Randy Teel, Ph.D., to the position of ...

Arvinas, Novartis collaborate for development, commercialization of ARV-766 for prostate cancer

12d ago, source: Daily

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, ...

Arvinas’ PROTAC pro tack: $1B-plus Novartis deal in prostate

15d ago, source: BioWorld

As Novartis AG’s approved prostate cancer therapy, Pluvicto (177Lu-PSMA-617), continues on a growth trajectory, the firm signed a licensing deal with Arvinas Inc. potentially valued at north of $1 ...

Arvinas gets grant for bifunctional compounds for modulating Tau protein

4d ago, source: Pharmaceutical Technology

Discover Arvinas Inc's groundbreaking patent for compounds targeting tau protein degradation, offering hope for Alzheimer's and other neurodegenerative diseases. Learn about the promising results and ...

Is Arvinas (ARVN) Stock a Solid Choice Right Now?

17d ago, source: Nasdaq

One stock that might be an intriguing choice for investors right now is Arvinas, Inc. ARVN. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

2d ago, source: Morningstar

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation ...

Arvinas Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...